STADA signs agreement to commercialize Rupafin® (rupatadine) in the MENA region
One documentmore
Stories about Stada Arzneimittel
STADA extends ViruProtect partnership with Enzymatica to cover Nordic region
One documentmoreSTADA extends ViruProtect partnership with Enzymatica to cover Nordic region
One documentmore
2Nico Reinhold new Global Head of Digital Communications at STADA
One documentmoreSTADA and PharmaMar sign agreement to commercialize Yondelis® (trabectedin) in the MENA region
One documentmoreEnyzmatica and STADA extend agreement on ViruProtect to Russia, Poland, Ukraine and CIS countries
One documentmoreEuropean Pharmaceutical Company STADA Enters Exclusive Medical Cannabis Partnership with MediPharm Labs
One documentmoreSTADA expands specialty footprint through acquisition of innovative therapy for treating advanced Parkinson's disease
One documentmoreSTADA's US partner Supernus submits NDA for apomorphine infusion pump
One documentmore-
Press release - Romaniszyn leads STADA Poland's growth strategy
One documentmore STADA continues to grow strongly during challenging times
One documentmorePress Release: Nidda Healthcare GmbH sets cash compensation for the transfer of the shares of the minority shareholders of STADA Arzneimittel AG at 98.51 EUR
One documentmoreDavidson Kempner Letter to Qiagen NV
more-
STADA Friday Fact: Look into the future - "Polypill" divides Europe
One documentmore Press release - New name - proven strengths: STADA GmbH becomes STADA Consumer Health Deutschland GmbH
One documentmore- 2
Press Release: STADA Health Report 2020 - Europe demands compulsory vaccinations
One documentmore KOPIE VON: Nidda Healthcare GmbH intends to conduct a squeeze-out of minority shareholders in STADA Arzneimittel AG under stock corporation law
One documentmoreNidda Healthcare GmbH intends to conduct a squeeze-out of minority shareholders in STADA Arzneimittel AG under stock corporation law
One documentmoreBausch + Lomb licenses exclusive rights from STADA and Xbrane to a biosimilar candidate for Lucentis (ranibizumab) in the United States and Canada
One documentmorePress release: STADA responds to urgent need by making more medicines than ever
One documentmorePress release: STADA delivers double-digit growth in 2019 as it invests to lead Consumer Healthcare and Generics core segments
One documentmorePress release: STADA delivers double-digit growth in 2019 as it invests to lead Consumer Healthcare and Generics core segments
One documentmorePress Release: STADA closes acquisition of Walmark, creating a winning portfolio for Central Europe
One documentmorePress release: STADA takes clear lead in Russian consumer healthcare sector
One documentmorePress release: STADA becomes a major Consumer Healthcare player by acquiring 15 well-established GSK brands
One documentmore-
Press release: Aidan Fry joins STADA's corporate communications team
One documentmore - 2
STADA to acquire established OTC and food supplement portfolio in the Philippines
One documentmore -
Press release: Wolfgang Ollig to become new CFO of the STADA Group
One documentmore -
STADA to Become a Major Pharma Player in Ukraine by Acquiring Biopharma's Pharmaceutical Prescription and Consumer Health Business
One documentmore Press release: STADA recognized as "Company of the year, EMEA" for the second year in a row
One documentmore
12Next